SCHEMBL1321920

SCHEMBL1321920

Cc1cc(Nc2ccc(O)cc2)nc(Nc2ccc(O)cc2)n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APOBEC3A P31941 1/20 0.68
APOBEC3G Q9HC16 1/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
PDPK1 O15530 1/20 0.59
SLC2A1 P11166 2/20 0.57
AURKA O14965 1/20 0.56
DOT1L Q8TEK3 3/20 0.55
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
IGF1R P08069 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
KDM4E B2RXH2 5/20 0.51
MAPT P10636 4/20 0.51
LMNA P02545 3/20 0.51
HTT P42858 3/20 0.51
NPSR1 Q6W5P4 2/20 0.51
GPR55 Q9Y2T6 1/20 0.51
USP2 O75604 1/20 0.51
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12340074 0.82 MAPT (0.71) APOBEC3AAPOBEC3GL3MBTL1PDPK1SLC2A1
SCHEMBL1319316 0.82 ABCG2 (0.66) APOBEC3AAPOBEC3GL3MBTL1PDPK1SLC2A1
SCHEMBL13531567 0.80 SLC2A1 (0.78) APOBEC3AAPOBEC3GL3MBTL1PDPK1SLC2A1
SCHEMBL4489132 0.80 RAB9A (0.51) APOBEC3AAPOBEC3GL3MBTL1AURKANPC1
SCHEMBL5959433 0.77 AURKA (0.59) AURKASMN1; SMN2KDM4EMAPTLMNA
SCHEMBL2409626 0.76 SLC2A1 (0.56) APOBEC3AAPOBEC3GL3MBTL1PDPK1SLC2A1
SCHEMBL13531371 0.74 SLC2A1 (0.68) APOBEC3AAPOBEC3GL3MBTL1PDPK1SLC2A1
SCHEMBL10036311 0.74 ROCK2 (0.76) NPC1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL22628619 0.74 RAB9A (0.65) APOBEC3AAPOBEC3GL3MBTL1SLC2A1NPC1
SCHEMBL16245079 0.73 OGG1 (0.74) APOBEC3AAPOBEC3GL3MBTL1PDPK1SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110275640-A1 Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound BTG INTERNATIONAL LTD. (GB) 2011-11-10 US disclosed
US-20110275641-A1 Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound BTG INTERNATIONAL LTD. (GB) 2011-11-10 US disclosed
US-8003645-B2 type II diabetes; 6-Ethyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine; suppress the fall in MTT reduction capacity by beta -amyloid protein; inhibit impairment of long-term potentiation of hippocampal nerve cells, pyrimidine or 1,3,5 triazine derivatives BTG INTERNATIONAL LTD. (GB) 2011-08-23 US disclosed
US-20090286794-A1 Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound BTG INTERNATIONAL LTD. (GB) 2009-11-19 US disclosed
US-20090286809-A1 Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound BTG INTERNATIONAL LTD. (GB) 2009-11-19 US disclosed
EP-1473289-B1 PREVENTIVES OR REMEDIES FOR ALZHEIMER'S DISEASE OR AMYLOID PROTEIN FIBROSIS INHIBITORS CONTAINING NITROGEN-CONTAINING HETEROARYL COMPOUNDS BTG INT LTD (GB) 2009-08-05 EP disclosed
US-20080182846-A1 Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound BTG INTERNATIONAL LIMITED (GB) 2008-07-31 US disclosed
EP-1473289-A1 PREVENTIVES OR REMEDIES FOR ALZHEIMER'S DISEASE OR AMYLOID PROTEIN FIBROSIS INHIBITORS CONTAINING NITROGEN-CONTAINING HETEROARYL COMPOUNDS Sankyo Company, Limited (JP) 2004-11-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275641-A1 Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound APP, BACE1, PSEN1 APOBEC3A 3089/4885APOBEC3G 3208/4885L3MBTL1 2732/4885
US-20090286794-A1 Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound APP, BACE1, PSEN1 APOBEC3A 3089/4885APOBEC3G 3208/4885L3MBTL1 2732/4885
US-20090286809-A1 Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound APP, BACE1, PSEN1 APOBEC3A 3089/4885APOBEC3G 3208/4885L3MBTL1 2732/4885
US-20080182846-A1 Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound APP, BACE1, PSEN1 APOBEC3A 3089/4885APOBEC3G 3208/4885L3MBTL1 2732/4885
US-20110275640-A1 Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound APP, BACE1, PSEN1 APOBEC3A 3089/4885APOBEC3G 3208/4885L3MBTL1 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.